Vivanza Biosciences Limited

Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting a standalone net loss of ₹96.54 lakhs for the year. Noted resignations of Non-Executi

Vivanza Biosciences reschedules its board meeting from May 4 to May 7, 2026 to approve audited results. The meeting will consider audited standalone and consolidated financial results for Q4 and year

Vivanza Biosciences discloses resignation of Company Secretary & Compliance Officer Mr. Chaitra Arora effective 30 April 2026. Resignation is due to personal career opportunities with no other materia

Vivanza Biosciences board meeting scheduled for May 4, 2026 to approve audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026. The trading window for insiders remain

Vivanza Biosciences Ltd filed promoter shareholding disclosures under SEBI SAST Regulation 31(4) for FY26. Promoter Hemant A. Parikh held 100,211 shares with no encumbrance during the financial year.

Vivanza Biosciences informs BSE that SEBI LODR Regulation 23(9) on related party transaction disclosures is not applicable to the company. The exemption is based on the company's paid-up equity capita